Cardiovascular risk in systemic inflammatory diseases;Il rischio cardiovascolare nelle patologie infiammatorie sistemiche

Giornale Italiano di Cardiologia

Volumn 14, Issue 7, 2013, Pages 517-525

  Marsico, Fabio ^a   Parente, Antonio ^a   Paolillo, Stefania ^a   Casaretti, Laura ^a   Lo Iudice, Francesco ^a   Pirozzi, Elisabetta ^a   Conte, Sirio ^a   Iardino, Elisabetta ^a   Gambardella, Francesco ^a   Della Ratta, Giuseppe Luca ^a   Cirillo, Annapaola ^a   Vitagliano, Alice ^a   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Coronary artery disease; Immune system; Systemic inflammatory diseases.

Indexed keywords

ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; IMMUNE SYSTEM; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSORIASIS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880862860     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: 10.1714/1308.14460     Document Type: Review

References (95)

1. Villalta D, Tozzoli R, Tonutti E, Bizzaro N. The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmun Rev 2007;6:359-65.
2. Vaudo G, Bocci EB, Shoenfeld Y, et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum 2005;52:3890-7.
3. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106. Descrive in maniera dettagliata l'implicazione del sistema immunitario nella genesi del processo aterosclerotico nelle principali malattie infiammatorie sistemiche.
4. Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanisms. Autoimmun Rev 2006;5:101-5.
5. Lee PY, Li Y, Richards HB et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69.
6. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus - mechanistic basis of the association. Curr Opin Immunol 2007;19:633-9.
7. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106:184-90.
8. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174-82.
9. Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-61.
10. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
11. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005;7:R984-R991.
12. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
13. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1489-97.
14. Ciftci O, Yilmaz S, Topcu S, et al. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 2008; 198:332-7.
15. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009;30:1837-43.
16. Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010;212:377-82.
17. Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009;68:453-5.
18. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
19. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
20. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-7. Descrive la fisiopatologia del pattern infiammatorio e la sua interferenza con la vulnerabilità della placca aterosclerotica.
21. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
22. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
23. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5. Descrive l'impatto degli eventi cardiovascolari sulla prognosi del lupus eritematoso sistemico proponendo un modello bimodale di mortalità.
24. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399- 406.
25. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
26. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
27. Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 2011;13:203.
28. Gustafsson J, Gunnarsson I, Börjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009;11:R186.
29. Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14:576-82.
30. Aringer M, Smolen JS. Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13:344-7.
31. Hirata K, Kadirvelu A, Kinjo M, et al. Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:1904-9.
32. Palmieri V, Migliaresi P, Orefice M, et al. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis 2009;19:234-40.
33. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-80.
34. Cederholm A, Svenungsson E, Stengel D, et al. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004;50:2869-76.
35. Belch JJ, McSwiggan S, Lau C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology 2008;47(Suppl 5): v16-v17.
36. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
37. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006;45:1395-8.
38. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976;53:483- 90.
39. Matucci Cerinic M, Valentini G, Sorano GG, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003;32:285-95.
40. Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999;31:195-214.
41. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55: 829-35.
42. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-75.
43. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. Descrive l'associazione tra psoriasi ed infarto miocardico in relazione all'età e alla gravità del quadro patologico.
44. Osto E, Piaserico S, Maddalozzo A, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis. Atherosclerosis 2012;221:113-7.
45. Shelling ML, Federman DG, Prodanovich S, Kirsner RS. Psoriasis and vascular disease: an unsolved mystery. Am J Med 2008;121: 360-5.
46. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145:700-3.
47. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
48. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
49. Gonzalez-Juanatey C, Llorca J, Amigo- Diaz E, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80.
50. Gonzalez-Juanatey C, Llorca J, Miranda- Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-93.
51. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
52. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
53. Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004;(1):CD003789.
54. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278.
55. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42.
56. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007;66: 1296-304.
57. Schaffer D, Florin T, Eagle C, et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 2006;185:501-6.
58. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-60.
59. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123:2226-35.
60. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction asso- ciated with the use of selective cyclooxygenase- 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113: 2906-13.
61. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
62. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.
63. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;(1): CD006356.
64. Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a metaanalysis. Rheumatology 2009;48:807-11.
65. Frostegard J. Cardiovascular co-morbidity in patients with rheumatic diseases. Arthritis Res Ther 2011;13:225.
66. Hafström I, Rohani M, Deneberg S, Wörnert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J Rheumatol 2007;34:1810-6.
67. del Rincón I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50:3813-22.
68. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125:14-22.
69. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005; 44:1414-21.
70. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real- world cohort study. J Intern Med 2013; 273:197-204.
71. Sazliyana S, Mohd Shahrir MS, Kong CT, Tan HJ, Hamidon BB, Azmi MT. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus 2011;12:1260-6.
72. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007;20:160-74.
73. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2010;49:295-307.
74. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
75. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009;11:R110.
76. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFαtreatment?alpha; in rheumatoid arthritis patients. Scand J Rheumatol 2009;38:6-10.
77. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6.
78. Macías I, García-Pérez S, Ruiz-Tudela M, Medina F, Chozas N, Girón-González JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-αblockade in patients with rheumatoid arthritis. J Rheumatol 2005;32:2102-8.
79. Kerekes G, Soltész P, Dér H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705-10.
80. Gonzalez-Juanatey C, Llorca J, Vazquez- Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximabtreated rheumatoid arthritis patients refractory to tumor necrosis factor αblocker therapy. Arthritis Rheum 2008;59:1821-4.
81. Gonzalez-Juanatey C, Testa A, Garcia- Castelo A, Garcia-Porrua C, Llorca J, Gonzalez- Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 2004; 51:447-50.
82. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFαtherapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-8.
83. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306:864-71. Questa metanalisi ha dimostrato che le terapie biologiche non aumentano l'incidenza di eventi cardiovascolari nei soggetti con psoriasi in trattamento con questa classe di farmaci.
84. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34.
85. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.
86. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143:1559-65.
87. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167: 1670-5.
88. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M. Excessive body weight and smoking associates with high risk of onset of plaque psoriasis. Acta Derm Venereol 2009;89:492-7.
89. Gisondi P, Cotena C, Tessari G, Girolomini G. Anti-tumor necrosis factor-αtherapy increases body weight in?alpha; patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-4.
90. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011;25:1007-11.
91. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012;223:1- 68.
92. Catapano AL, Reiner Z, De Backer G, et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46.
93. Perrone-Filardi P, Cuocolo A, Brevetti G, et al. Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patients with peripheral arterial disease. Am J Cardiol 2005;96:1337- 41.
94. Pellegrino T, Storto G, Filardi PP, et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med 2005;46:1997-2002.
95. Perrone-Filardi P, Achenbach S, Möhlenkamp S, et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur Heart J 2011;32:1986-93.